TICAGRELOR

Question 1

IND

Answer 1

STEMI, in conjunction with the primary PCI pathway, when requested by the accepting clinician.

Question 2

MECHNISM

Answer 2

icagrelor has antiplatelet activity. It produces reversible inhibition of the ADP receptor on platelets, decreasing platelet aggregation.

Question 3

CONTRAS

Answer 3

allergy

Question 4

CAUTIONS

Answer 4

Clinically significant bleeding. Ticagrelor will increase bleeding.

At risk of bleeding.

Pregnancy.

Question 5

dose

Answer 5

180 mg PO ( 2 tablets )

Question 6

common adverse effects

Answer 6

increased bleeding

Question 7

onset

Answer 7

30-60

Question 8

duration

Answer 8

24 H

Question 9

common interactions

Answer 9

The risk of bleeding will be increased if the patient is taking an anticoagulant.

Question 10

why do we want to inhibit ADP in the context of a STEMI

Answer 10

ADP catalyses the aggregation of platelets, thus increasing the size of the thrombus.

As platelets accumulate, they release chemicals that in turn attract more platelets in a positive feedback loop

thus, inhibiting ADP, inhibits this feedback loop